Xiao-Lei Huang1, Li Zhang2, Yu Duan1, Yu-Jie Wang1, Jing Wang3. 1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China. 2. Medical Genetics Center, Anhui Medical College, Hefei, China. 3. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China. Electronic address: jwang2006@126.com.
Abstract
BACKGROUND AND AIMS: Pentraxin 3 (PTX3) plays an important role in the inflammatory processes. Recently it has been reported to be involved in autoimmune diseases. Many studies have investigated the serum/plasma levels of PTX3 in autoimmune diseases, but the results are contradictory or inconclusive among those findings. The purpose of this meta-analysis was to investigate whether serum/plasma levels of PTX3 were associated with autoimmune diseases by comparing the serum/plasma levels of PTX3 in the autoimmune diseases and healthy controls. METHODS: PubMed, ELSEVIER ScienceDirect and Cochrane Library databases (up to December 26, 2015) were used to obtain all relative published literatures. The study quality was assessed by the Newcastle-Ottawa scale. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated by random-effect model analysis. RESULTS: A total of 20 studies including seven studies of systemic lupus erythematosus (SLE), four studies of ankylosing spondylitis (AS), five studies of rheumatoid arthritis (RA), three studies of systemic sclerosis (SSc) and one study of multiple sclerosis (MS) were finally included in the meta-analysis. The results revealed that the serum/plasma levels of PTX3 in autoimmune diseases were significantly higher than in normal controls (SMD = 0.496 ng/mL, 95% CI = 0.107-0.886, p <0.001; I(2) = 91.9, p <0.001). The subgroup analysis showed that the serum/plasma levels of PTX3 in AS and SSc were higher than in healthy controls (pooled SMD = 0.926 ng/mL, 95% CI = 0.174-1.677, p <0.001, I(2) = 77.0, p = 0.013; pooled SMD = 0.546 ng/mL, 95% CI = 0.136-0.957, p <0.001; I(2) = 30.9, p = 0.299, respectively). CONCLUSIONS: Serum/plasma levels of PTX3 in autoimmune diseases were higher than in normal controls.
BACKGROUND AND AIMS: Pentraxin 3 (PTX3) plays an important role in the inflammatory processes. Recently it has been reported to be involved in autoimmune diseases. Many studies have investigated the serum/plasma levels of PTX3 in autoimmune diseases, but the results are contradictory or inconclusive among those findings. The purpose of this meta-analysis was to investigate whether serum/plasma levels of PTX3 were associated with autoimmune diseases by comparing the serum/plasma levels of PTX3 in the autoimmune diseases and healthy controls. METHODS: PubMed, ELSEVIER ScienceDirect and Cochrane Library databases (up to December 26, 2015) were used to obtain all relative published literatures. The study quality was assessed by the Newcastle-Ottawa scale. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated by random-effect model analysis. RESULTS: A total of 20 studies including seven studies of systemic lupus erythematosus (SLE), four studies of ankylosing spondylitis (AS), five studies of rheumatoid arthritis (RA), three studies of systemic sclerosis (SSc) and one study of multiple sclerosis (MS) were finally included in the meta-analysis. The results revealed that the serum/plasma levels of PTX3 in autoimmune diseases were significantly higher than in normal controls (SMD = 0.496 ng/mL, 95% CI = 0.107-0.886, p <0.001; I(2) = 91.9, p <0.001). The subgroup analysis showed that the serum/plasma levels of PTX3 in AS and SSc were higher than in healthy controls (pooled SMD = 0.926 ng/mL, 95% CI = 0.174-1.677, p <0.001, I(2) = 77.0, p = 0.013; pooled SMD = 0.546 ng/mL, 95% CI = 0.136-0.957, p <0.001; I(2) = 30.9, p = 0.299, respectively). CONCLUSIONS: Serum/plasma levels of PTX3 in autoimmune diseases were higher than in normal controls.
Authors: Line Jee Hartmann Rasmussen; Martin Schultz; Anne Gaardsting; Steen Ladelund; Peter Garred; Kasper Iversen; Jesper Eugen-Olsen; Morten Helms; Kim Peter David; Andreas Kjaer; Anne-Mette Lebech; Gitte Kronborg Journal: Int J Cancer Date: 2017-04-24 Impact factor: 7.396
Authors: Gia Deyab; Ingrid Hokstad; Jon Elling Whist; Milada Cvancarova Småstuen; Stefan Agewall; Torstein Lyberg; Barbara Bottazzi; Pier Luigi Meroni; Roberto Leone; Gunnbjorg Hjeltnes; Ivana Hollan Journal: PLoS One Date: 2017-02-22 Impact factor: 3.240
Authors: Nina B Burkhardt; Susanne Röll; Anke Staudt; Daniel Elleder; Sonja Härtle; Taiana Costa; Andreas Alber; Mark P Stevens; Lonneke Vervelde; Benjamin Schusser; Bernd Kaspers Journal: Front Immunol Date: 2019-02-01 Impact factor: 7.561
Authors: Andy Judge; Cesar Garriga; Nigel K Arden; Simon Lovestone; Dani Prieto-Alhambra; Cyrus Cooper; Christopher J Edwards Journal: Alzheimers Dement (N Y) Date: 2017-11-09